NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation

NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation

Glioblastoma multiforme (GBM) is a highly heterogeneous disease with a mesenchymal subtype tending to exhibit more aggressive and multitherapy-resistant features. Glioblastoma stem-cells derived from mesenchymal cells are reliant on iron supply, accumulated with high reactive oxygen species (ROS), a...

Full description

Bibliographic Details
Main Authors: Fong, I.-H (Author), Lin, C.-M (Author), Liu, H.-W (Author), Setiawan, S.A (Author), Su, I.-C (Author), Su, Y.-K (Author), Yadav, V.K (Author), Yeh, C.-T (Author)
Format: Article
Language:English
Published: MDPI 2023
Subjects:
alkylating agent
animal
Animals
Antineoplastic Agents, Alkylating
Brain Neoplasms
brain tumor
Cell Line, Tumor
CYBB
CYBB protein, human
Cybb protein, mouse
drug resistance
Drug Resistance, Neoplasm
erastin
ferroptosis
genetics
glioblastoma
Glioblastoma
human
Humans
mesenchymal
metabolism
Mice
mouse
NADPH Oxidase 2
NF-E2-Related Factor 2
pathology
reactive oxygen metabolite
Reactive Oxygen Species
reduced nicotinamide adenine dinucleotide phosphate oxidase 2
SOD2
temozolomide
Temozolomide
transcription factor Nrf2
tumor cell line
Online Access:View Fulltext in Publisher
View in Scopus

Internet

View Fulltext in Publisher
View in Scopus

Similar Items